CDK2 and hepatocellular carcinoma: Xylocydine is a novel cyclin-dependent kinase (cdk) inhibitor that induces apoptosis in hepatocellular carcinoma (HCC) cells by inhibiting Cdk1, Cdk2, Cdk7, and Cdk9 activities [25,26].